A video consultation between patient and surgeon is just as good as a physical visit to the outpatient clinic to discuss a ...

A video consultation between patient and surgeon is just as good as a physical visit to the outpatient clinic to discuss a ...

Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for chemotherapy in certain patients with NSCLC.

Ravindra Uppaluri, MD, PhD, discusses findings from the KEYNOTE-689 trial in adult patients with resectable, locally advanced head and neck squamous cell carcinoma.

Virtual consultations hold the potential to transform patient care; however, their capacity to fully replace face-to-face interactions remains uncertain. ten Haaft and colleagues present findings from ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the ...

Setting Secondary care. Participants Patients (≥18 years) undergoing major elective surgery (curative or palliative). Interventions Any intervention administered in the preoperative period with the ...

Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free ...

FDA has approved perioperative pembrolizumab for resectable head and neck squamous cell carcinoma, but do patients need ...

Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

The agency approved a perioperative Keytruda regimen based on a 30 percent reduction in the risk of recurrence, progression, or death versus the control arm.